Latest Novocure News & Updates

See the latest news and media coverage for Novocure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novocure

Global oncology company

novocure.com

Headquarters: Baar, Switzerland
Founded year: 2000
Company type: Public company
Number of employees: 1,500–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Novocure

In short: Novocure reported record Q2 2026 revenue of $184 million and secured FDA and CE Mark approvals for its Optune Pax pancreatic cancer therapy.

Company announcements

July 23 Novocure

Novocure reports Q2 2026 financial results with 16% revenue growth

Net revenues reached $184 million, driven by 18% active patient growth, and CE Mark for Optune Pax in locally advanced pancreatic cancer.

July 1 Novocure

Novocure will report Q2 2026 financial results

The company will host a conference call at 8 a.m. EDT on July 23 to discuss results.

June 30 Novocure

Novocure receives CE Mark for pancreatic cancer treatment

The CE Mark is based on Phase 3 PANOVA-3 trial showing improved overall survival and delayed pain progression.

June 18 Novocure

Novocure announced topline data from Phase 3 TRIDENT trial

The trial did not meet its primary endpoint of overall survival in the ITT population. No new safety signals were observed.

Media coverage

July 27 Yahoo Finance

Novocure Ltd.

Visit a quote page and your recently viewed tickers will be displayed here.

Never miss news about Novocure

Track Novocure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.